Your session is about to expire
← Back to Search
JNJ-86974680 + Radiation Therapy + Cetrelimab for Non-Small Cell Lung Cancer
Study Summary
This trial studies a new drug combo to see if it's safe & effective for cancer treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current capacity of this clinical trial?
"Affirmative. Data available on clinicaltrials.gov suggests that this experiment has been accepting participants since November 20th, 2023 after the latest update was made on November 8th of the same year. Two medical sites are looking to recruit a total of seventy-six patients for this trial."
Are there any open recruitment opportunities for this research endeavor?
"According to the information on clinicaltrials.gov, this investigation is actively searching for participants and has been since it was first uploaded in November 20th of 2022. The data was last updated a month later, as recently as November 8th of 2022."
Has the combination of JNJ-86974680 and Cetrelimab been granted authorization by the FDA?
"Due to the infancy of Phase 1 trials, our team gave JNJ-86974680+Cetrelimab a score of one on the safety scale. This is based upon limited data indicating its efficacy and lack thereof for safety."
What objectives have been identified for this clinical endeavor?
"According to information reported by Johnson & Johnson Enterprise Innovation Inc., the primary outcome, which will be measured over a Up to 2 years 5 month duration, is the number of participants experiencing adverse events (AEs) sorted according to severity. Secondary outcomes such as apparent volume of distribution (V/F), complete response rate (CRR), and duration of response (DOR) will also be evaluated. V/F indicates theoretical drug concentration in plasma while CRR represents proportion of patients with best responses documented as 'complete response' and DOR denotes time between initial documentation of response until progression or death due to any cause."
Share this study with friends
Copy Link
Messenger